Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924352 · ClinicalTrials.gov registry record · Phase 1
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
A Phase 1 study, sponsored by Accelerated Community Oncology Research Network.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00924352 is a Phase 1 study that has completed, run by Accelerated Community Oncology Research Network. The registered enrollment target is 56 participants.
The verdict
NCT00924352, a Phase 1 study, has completed, sponsored by Accelerated Community Oncology Research Network.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The primary objective for the Phase I portion of the study is to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) and for the Phase II portion of the study is to evaluate progression free survival (PFS). Secondary objectives are response rate, clinical benefit rate, and overall toxicity.
Interventions
- DRUG Dasatinib
- DRUG Ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00924352
The ClinicalTrials.gov registry entry for NCT00924352 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accelerated Community Oncology Research Network, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT00924352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00924352 about?
NCT00924352 is a clinical study titled "Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer". The primary objective for the Phase I portion of the study is to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) and for the Phase II portion of the study is to evaluate progression free survival (PFS). Secondary objectives are response rate, clinical benefit rate, and...
What is the current status of trial NCT00924352?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2009-06. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00924352?
The interventions under investigation include: Dasatinib (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00924352?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.